These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 8543019)

  • 1. Interaction of cryptophycin 1 with tubulin and microtubules.
    Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
    FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin.
    Smith CD; Zhang X
    J Biol Chem; 1996 Mar; 271(11):6192-8. PubMed ID: 8626409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
    Mooberry SL; Taoka CR; Busquets L
    Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
    Panda D; Himes RH; Moore RE; Wilson L; Jordan MA
    Biochemistry; 1997 Oct; 36(42):12948-53. PubMed ID: 9335554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
    Bai R; Durso NA; Sackett DL; Hamel E
    Biochemistry; 1999 Oct; 38(43):14302-10. PubMed ID: 10572005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the antitumor compound cryptophycin-52 with tubulin.
    Panda D; Ananthnarayan V; Larson G; Shih C; Jordan MA; Wilson L
    Biochemistry; 2000 Nov; 39(46):14121-7. PubMed ID: 11087360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells.
    Smith CD; Zhang X; Mooberry SL; Patterson GM; Moore RE
    Cancer Res; 1994 Jul; 54(14):3779-84. PubMed ID: 7913408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
    Bai R; Friedman SJ; Pettit GR; Hamel E
    Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the interaction of cryptophycin 1 with tubulin: binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction.
    Bai R; Schwartz RE; Kepler JA; Pettit GR; Hamel E
    Cancer Res; 1996 Oct; 56(19):4398-406. PubMed ID: 8813133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
    Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
    J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localization of the antimitotic peptide and depsipeptide binding site on beta-tubulin.
    Mitra A; Sept D
    Biochemistry; 2004 Nov; 43(44):13955-62. PubMed ID: 15518544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
    Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
    Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
    Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
    Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: molecular modeling of the mechanism of action of a new antimitotic drug.
    Barbier P; Gregoire C; Devred F; Sarrazin M; Peyrot V
    Biochemistry; 2001 Nov; 40(45):13510-9. PubMed ID: 11695898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
    Bai R; Cichacz ZA; Herald CL; Pettit GR; Hamel E
    Mol Pharmacol; 1993 Oct; 44(4):757-66. PubMed ID: 8232226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiochemical aspects of tubulin-interacting antimitotic drugs.
    Correia JJ; Lobert S
    Curr Pharm Des; 2001 Sep; 7(13):1213-28. PubMed ID: 11472263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)-Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerization.
    Kanoh K; Kohno S; Katada J; Takahashi J; Uno I
    J Antibiot (Tokyo); 1999 Feb; 52(2):134-41. PubMed ID: 10344567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.
    Matthew S; Chen QY; Ratnayake R; Fermaintt CS; Lucena-Agell D; Bonato F; Prota AE; Lim ST; Wang X; Díaz JF; Risinger AL; Paul VJ; Oliva MÁ; Luesch H
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
    Bai RL; Pettit GR; Hamel E
    J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bridging the maytansine and vinca sites: Cryptophycins target β-tubulin's T5-loop.
    Abel AC; Mühlethaler T; Dessin C; Schachtsiek T; Sammet B; Sharpe T; Steinmetz MO; Sewald N; Prota AE
    J Biol Chem; 2024 Jun; 300(6):107363. PubMed ID: 38735475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.